Michael Lewis, DO
Family Medicine · Indianapolis, INNPI 1487189510
Payments from drug & device makers
Across 235 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$864
- AbbVie$837
- Lilly USA, LLC$419
- AstraZeneca$302
- Pfizer$272
- Boehringer Ingelheim$194
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,981100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $864 |
| AbbVie | 47 | $837 |
| Lilly USA, LLC | 29 | $419 |
| AstraZeneca | 16 | $302 |
| Pfizer | 18 | $272 |
| Boehringer Ingelheim | 12 | $194 |
| Exact Sciences | 8 | $144 |
| Otsuka America Pharmaceutical, Inc. | 5 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $83 |
| Axsome Therapeutics, Inc. | 4 | $78 |
| Tempus AI, Inc | 3 | $69 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $67 |
| Astellas Pharma US Inc | 3 | $67 |
| Abbott | 3 | $65 |
| Dynavax Technologies Corporation | 3 | $54 |
| Edwards Lifesciences | 2 | $48 |
| Idorsia Pharmaceuticals US Inc | 3 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $41 |
| Halozyme Inc | 2 | $34 |
| Amgen | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Dexcom, Inc. | 1 | $21 |
| Tris Pharma Inc | 1 | $18 |
| Merck | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| GSK | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Mylan Specialty L.p. | 1 | $12 |
How this compares
$3,981 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 103 | $119,599 |
| OzempicSemaglutide | 82 | $86,702 |
| FarxigaDapagliflozin Propanediol | 38 | $43,556 |
| MounjaroTirzepatide | 40 | $41,062 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $26,262 |
| JanuviaSitagliptin Phosphate | 13 | $17,080 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $13,136 |
| EliquisApixaban | 12 | $10,397 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 23 | $7,282 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,905 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,191 |
| Gabapentin | 151 | $3,947 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $3,929 |
| Atorvastatin Calcium | 387 | $2,938 |
| Duloxetine Hcl | 80 | $1,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $194 | $119,599103 claims |
| Novo NordiskOzempic | $864 | $86,70282 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta | $13 | $47,51776 claims |
| AstraZenecaFarxiga | $302 | $43,55638 claims |
| Lilly USA, LLCMounjaro | $419 | $41,06240 claims |
| PfizerEliquis, Abrysvo | $272 | $17,67835 claims |
| MerckJanuvia | $17 | $17,08013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Blair BrengleIndianapolis$10.6M
- Steven SmithIndianapolis$2.5M
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Gaylen KeltonIndianapolis$42K
- Daniela LoboIndianapolis$38K
- Haihong MaoIndianapolis$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.